Lixte Biotechnology Holdings

General Information
Business:

(Note: This is not an IPO. This is an up-listing, or a step-up, to the NASDAQ from the OTCQB Marketplace. The company’s stock trades under the symbol “LIXT” on the OTCQB Marketplace, where it is quoted at around $1.18.)

We are a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases and then designs novel compounds to attack those targets. Our product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and/or X-ray and immune checkpoint blockers.

Our leading product candidates are the LB-100 series, which consists of novel structures which have the potential to be first in their class and may be useful in treating several types of cancer as well as vascular and metabolic diseases, and the LB-200 series, which may be useful in treating chronic hereditary diseases such as Gaucher’s disease, in addition to cancer and neurodegenerative diseases.

 

 

 

 

Industry: Pharmaceuticals
Employees: 4
Founded: 2005
Contact Information
Address 248 Route 25A, No. 2 East Setauket, NY 11733
Phone Number (631) 880-2907
Web Address http://www.lixte.com
View Prospectus: Lixte Biotechnology Holdings
Financial Information
Market Cap
Revenues $0 mil (last 12 months)
Net Income $-2.2 mil (last 12 months)
IPO Profile
Symbol LIXT
Exchange NASDAQ
Shares (millions): 0.0
Price range $0.00 - $0.00
Est. $ Volume $10.7 mil
Manager / Joint Managers WestPark Capital
CO-Managers
Expected To Trade:
Status: TBA
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change